IDEXX Laboratories Inc
IDXX- Exchange
- Nasdaq
- Industry
- In Vitro & In Vivo Diagnostic Substances
- SEC CIK
- 0000874716
In the last 90 days, IDEXX Laboratories Inc insiders filed 0 open-market purchases and 1 sale; 1,306 institutions reported holding it in 13F filings for Q2 2026, worth $39.2B in total; 3 superinvestors hold it, including Fundsmith and Weitz Investment Management.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $1.17M in total
- 1
- 13F holdersQ2 2026, +9 vs. previous quarter
- 1,306
- 13F valueReported value at the end of Q2 2026
- $39.2B
- Superinvestors holdingAt the end of Q2 2026
- 3
Price chart
Superinvestors holding IDXX, Q2 2026
3 superinvestors report holding IDEXX Laboratories Inc on Form 13F. Percentages are the stock's share of each portfolio.
Weitz Investment Management
Wally Weitz
1.3%
IDEXX Laboratories Inc's share of the portfolio
- Shares
- 35,300
- Value
- $18.6M
| Superinvestor | Weight | Value |
|---|---|---|
| Harris Associates (Oakmark) | <0.1% | $239.5K |
Latest insider trades
Open-market purchases and sales by IDEXX Laboratories Inc insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 9, 2026 (view filing)5:00 PM ET | Sep 4 | 5 days | Kingsley Lawrence DDirector | SSale | −2.20K | $532.08 | −$1.17M | −18.7%9.57K after | |
| Mar 5, 2026 (view filing) | Mar 3 | 2 days | Hunt NimrataExecutive Vice President | SSale | −1.76K | $634.57 | −$1.12M | −8.8%18.1K after | |
| Mar 2, 2026 (view filing) | Feb 26 | 4 days | Mazelsky Jonathan JayPresident and CEO | SSale | −23.3K | $657.55 | −$15.3M | −21.8%83.6K after | 13 lots |
| Feb 27, 2026 (view filing) | Feb 26 | 1 day | Hunt NimrataExecutive Vice President | SSale | −2.69K | $661.54 | −$1.78M | −11.9%19.9K after | |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Erickson Michael GExecutive Vice President | SSale | −5.37K | $627.38 | −$3.37M | −29.7%12.7K after | 6 lots |
| Feb 19, 2026 (view filing) | Feb 17 | 2 days | Vandebroek Sophie V.Director | SSale | −1.46K | $628.62 | −$920.3K | −69.3%648 after | 2 lots |
| Feb 11, 2026 (view filing) | Feb 10 | 1 day | Fennell GeorgeExecutive Vice President | SSale | −11.3K | $646.72 | −$7.34M | −53.6%9.82K after | 8 lots |
| Nov 10, 2025 (view filing) | Nov 7 | 3 days | Hunt NimrataExecutive Vice President | SSale | −9.43K | $703.34 | −$6.63M | −30.8%21.1K after | 4 lots |
| Aug 26, 2025 (view filing) | Aug 22 | 4 days | Szostak M AnneDirector | SSale | −2.19K | $647.33 | −$1.42M | −89.3%262 after | |
| Aug 14, 2025 (view filing) | Aug 12 | 2 days | Erickson Michael GExecutive Vice President | SSale | −405.89 | $649.96 | −$263.8K | −3.5%11.3K after | 2 lots |
Top 10 13F holders, Q2 2026
The largest institutional positions in IDEXX Laboratories Inc at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| BlackRock, Inc. | 8,170,178 | $4.30B | 0.06% | −195,375−2.3% | Reduced |
| Vanguard Capital Management LLC | 5,152,213 | $2.71B | 0.06% | −30,294−0.6% | Reduced |
| Vanguard Portfolio Management LLC | 3,896,521 | $2.05B | 0.09% | −14,342−0.4% | Reduced |
| State Street Corp | 3,748,660 | $1.97B | 0.06% | +74,475+2.0% | Added |
| Invesco Ltd. | 3,611,416 | $1.90B | 0.15% | +261,739+7.8% | Added |
| Geode Capital Management, LLC | 2,562,886 | $1.35B | 0.07% | −98,113−3.7% | Reduced |
| Bamco Inc | 1,976,778 | $1.04B | 1.56% | +343,411+21.0% | Added |
| Morgan Stanley | 1,356,103 | $713.9M | 0.04% | +40,149+3.1% | Added |
| Bank of New York Mellon Corp | 1,193,343 | $628.2M | 0.10% | −311,189−20.7% | Reduced |
| Arrowstreet Capital, Limited Partnership | 1,067,078 | $561.8M | 0.25% | +228,239+27.2% | Added |